Friday, 29 March 2024


Johnson & Johnson acquires Aragon Pharma

21 August 2013 | News | By BioSpectrum Bureau

Johnson & Johnson acquires Aragon Pharma

Johnson & Johnson acquires Aragon Pharma

Singapore: Johnson & Johnson has acquired Aragon Pharmaceuticals, a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.

Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development.

"The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Dr Peter F Lebowitz, head, global therapeutic area, Oncology.

"It builds on our existing leadership position with Zytiga (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients," he added. 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account